Sugi Predict

Sugi Predict / Compounds / SCHEMBL659053

SCHEMBL659053

SCHEMBL659053

COc1ccc(CCNC(C)=O)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 1/20 1.00
▸ GLA P06280 1/20 0.67
▸ KMT2A Q03164 1/20 0.67
▸ KDM4E B2RXH2 2/20 0.66
▸ F13A1 P00488 1/20 0.66
▸ MTNR1A P48039 1/20 0.65
▸ MTNR1B P49286 1/20 0.65
▸ TAAR1 Q96RJ0 2/20 0.63
▸ ALDH1A1 P00352 1/20 0.63
▸ FPR2 P25090 1/20 0.61
▸ ACACB O00763 1/20 0.61
▸ LMNA P02545 1/20 0.61
▸ NPC1 O15118 1/20 0.60
▸ GAA P10253 1/20 0.60
▸ RAB9A P51151 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30858767 0.87 SMN1; SMN2 (0.77) SMN1; SMN2GLAKMT2AKDM4ETAAR1
SCHEMBL17919369 0.87 SMN1; SMN2 (0.77) SMN1; SMN2GLAKMT2AKDM4ETAAR1
SCHEMBL10592850 0.87 KDM4E (0.84) SMN1; SMN2KDM4EF13A1MTNR1AMTNR1B
SCHEMBL4583404 0.86 SMN1; SMN2 (0.75) SMN1; SMN2GLAKMT2AKDM4ETAAR1
SCHEMBL12773610 0.86 SMN1; SMN2 (0.75) SMN1; SMN2GLAKMT2ATAAR1ALDH1A1
SCHEMBL5944191 0.86 SMN1; SMN2 (0.75) SMN1; SMN2GLAKMT2AKDM4ETAAR1
SCHEMBL4322629 0.86 GLA (0.77) SMN1; SMN2GLAKMT2AKDM4ETAAR1
SCHEMBL3719877 0.85 SMN1; SMN2 (0.74) SMN1; SMN2KDM4EMTNR1AMTNR1BLMNA
SCHEMBL6965266 0.84 SMN1; SMN2 (0.73) SMN1; SMN2KMT2AKDM4EF13A1TAAR1
SCHEMBL159655 0.84 SMN1; SMN2 (0.73) SMN1; SMN2GLAKMT2AKDM4ETAAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4739625-B2 — — 2011-08-03 — — JP claimed
US-20060058553-A1 Novel bicyclic hydroxamates as inhibitors of histone deacetylase AXYS PHARMACEUTICALS, INC. (US) 2006-03-16 — — US claimed
EP-1472216-A2 NOVEL BICYCLIC HYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE Axys Pharmaceuticals (US) 2004-11-03 — — EP claimed
WO-2003066579-A2 NOVEL BICYCLIC HYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE AXYS PHARMACEUTICALS (US) 2003-08-14 — — WO claimed
EP-1206467-A1 N-HETEROCYCLIC DERIVATIVES AS NOS INHIBITORS BERLEX LABORATORIES, INC. (US) 2002-05-22 — — EP claimed
WO-2001014371-A1 N-HETEROCYCLIC DERIVATIVES AS NOS INHIBITORS BERLEX LABORATORIES, INC. (US) 2001-03-01 — — WO claimed
US-20260138987-A1 MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS CONTINEUM THERAPEUTICS INC (US) 2026-05-21 — — US disclosed
US-12565501-B2 Muscarinic acetylcholine M1 receptor antagonists CONTINEUM THERAPEUTICS, INC. (US) 2026-03-03 — — US disclosed
US-20250171455-A1 MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS CONTINEUM THERAPEUTICS INC (US) 2025-05-29 — — US disclosed
CN-115594669-B Parallel ring derivative and preparation method and medical application thereof 深圳信立泰药业股份有限公司 2024-11-05 — — CN disclosed
US-20230089921-A1 MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS CONTINEUM THERAPEUTICS, INC. 2023-03-23 — — US disclosed
CN-115594669-A Fused ring derivative and preparation method and medical application thereof 深圳信立泰药业股份有限公司（CN） 2023-01-13 — — CN disclosed
CN-114729044-A Muscarinic acetylcholine M1Receptor antagonists 帕珀莱恩医疗公司 2022-07-08 — — CN disclosed
WO-2003066579-A2 NOVEL BICYCLIC HYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE AXYS PHARMACEUTICALS (US) 2003-08-14 — — WO disclosed
EP-1015444-B1 PYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF YUHAN CORP LTD (KR) 2003-05-28 — — EP disclosed
EP-1206467-A1 N-HETEROCYCLIC DERIVATIVES AS NOS INHIBITORS BERLEX LABORATORIES, INC. (US) 2002-05-22 — — EP disclosed
US-6352993-B1 ANTIULCER AGENTS YUHAN CORPORATION (KR) 2002-03-05 — — US disclosed
WO-2001014371-A1 N-HETEROCYCLIC DERIVATIVES AS NOS INHIBITORS BERLEX LABORATORIES, INC. (US) 2001-03-01 — — WO disclosed
EP-1015444-A1 NOVEL PYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF YUHAN CORPORATION, LTD. (KR) 2000-07-05 — — EP disclosed
WO-1998043968-A1 NOVEL PYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF YUHAN CORPORATION (KR) 1998-10-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12565501-B2 Muscarinic acetylcholine M1 receptor antagonists CHRM1, CHRM2, CHRM3 SMN1; SMN2 2355/4885GLA 2367/4885KMT2A 1589/4885
US-20230089921-A1 MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS CHRM1, CHRM2, CHRM3 SMN1; SMN2 1261/4885GLA 1458/4885KMT2A 1093/4885
US-20260138987-A1 MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS CHRM1, CHRM5, CHRM3 SMN1; SMN2 1733/4885GLA 2742/4885KMT2A 1878/4885
US-20250171455-A1 MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS CHRM1, CHRM2, CHRM3 SMN1; SMN2 1247/4885GLA 1452/4885KMT2A 1077/4885
US-20060058553-A1 Novel bicyclic hydroxamates as inhibitors of histone deacetylase HDAC1, HDAC2, HDAC11 SMN1; SMN2 2943/4885GLA 673/4885KMT2A 100/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.